Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
10
×
life sciences
national blog main
new york top stories
10
×
new york blog main
national top stories
biotech
san francisco top stories
boston blog main
boston top stories
san francisco blog main
amgen
fda
raleigh-durham blog main
raleigh-durham top stories
indiana blog main
indiana top stories
national
new york
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe top stories
inclisiran
novartis
regeneron pharmaceuticals
roche
biogen
bristol-myers squibb
cancer
What
drug
10
×
fda
patients
cholesterol
market
medco
medicine
medicines
new
pricing
approval
approved
bio
brings
cancer
friday
immunotherapy
lowering
oral
roundup
therapy
twice
type
aces
acquire
activity
advanced
advantages
agency
agreed
aimmune
allergy
announced
arrival
atrophy
award
awarded
bar
bid
big
Language
unset
10
×
Current search:
drug
×
unset
×
" new york top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs